Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report report published on Thursday morning. The firm issued a sell rating on the stock.

Bio-Path Stock Performance

Shares of BPTH stock opened at $0.18 on Thursday. The company’s 50 day moving average price is $0.36 and its two-hundred day moving average price is $0.73. Bio-Path has a 52 week low of $0.12 and a 52 week high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.